Clinical features in 345 patients, 1994-2002
. | Younger than 65 y . | 65 y old or older . | P . |
|---|---|---|---|
| No. patients (%) | 280 (81) | 65 (19) | — |
| Median age, y (range) | 55 (29-64) | 68 (65-79) | < .001 |
| Time from symptoms to diagnosis, mo | 12.4 ± 20.4 | 11.7 ± 15.9 | .807 |
| Time from diagnosis to referral, mo | 6.0 ± 13.8 | 7.0 ± 19.3 | .614 |
| Male, % | 57 | 72 | .022 |
| λ, % | 84 | 82 | .640 |
| Median no. of organs | 2.3 | 2.4 | .715 |
| Cardiac involvement, % | 44.3 | 42.4 | .837 |
| Performance status | 1.1 | 1 | .690 |
| Eligible for HDM/SCT, %* | 68.4 | 34.3 | < .001 |
| Collection complications, % | 10.4 | 12.3 | .647 |
| Received 200 mg/m2 melphalan, % | 65.0 | 19.0 | < .001 |
| Treatment-related mortality, % | 13.4 | 10.3 | .665 |
| 1-y mortality, % | 26.8 | 27.6 | .882 |
| Hematologic CR, % | 43.5 | 32.0 | .191 |
| Median survival, y | 4.85 | 3.98 | .28 |
. | Younger than 65 y . | 65 y old or older . | P . |
|---|---|---|---|
| No. patients (%) | 280 (81) | 65 (19) | — |
| Median age, y (range) | 55 (29-64) | 68 (65-79) | < .001 |
| Time from symptoms to diagnosis, mo | 12.4 ± 20.4 | 11.7 ± 15.9 | .807 |
| Time from diagnosis to referral, mo | 6.0 ± 13.8 | 7.0 ± 19.3 | .614 |
| Male, % | 57 | 72 | .022 |
| λ, % | 84 | 82 | .640 |
| Median no. of organs | 2.3 | 2.4 | .715 |
| Cardiac involvement, % | 44.3 | 42.4 | .837 |
| Performance status | 1.1 | 1 | .690 |
| Eligible for HDM/SCT, %* | 68.4 | 34.3 | < .001 |
| Collection complications, % | 10.4 | 12.3 | .647 |
| Received 200 mg/m2 melphalan, % | 65.0 | 19.0 | < .001 |
| Treatment-related mortality, % | 13.4 | 10.3 | .665 |
| 1-y mortality, % | 26.8 | 27.6 | .882 |
| Hematologic CR, % | 43.5 | 32.0 | .191 |
| Median survival, y | 4.85 | 3.98 | .28 |
— indicates not applicable.
Percent eligible of 450 patients younger than 65 y and 251 patients at least 65 y of age screened for HDM/SCT.